Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
For the design of potent subunit vaccines, it is of paramount importance to identify all antigens immunologically recognized by a patient population infected with a pathogen. We have developed a rapid and efficient procedure to identify such commonly recognized antigens, and here we provide a comprehensive in vivo antigenic profile of Staphylococcus aureus , an important human pathogen. S. aureus peptides were displayed on the surface of Escherichia coli via fusion to one of two outer membrane proteins (LamB and FhuA) and probed with sera selected for high Ab titer and opsonic activity. A total of 60 antigenic proteins were identified, most of which are located or predicted to be located on the surface of the bacterium or secreted. The identification of these antigens and their reactivity with individual sera from patients and healthy individuals greatly facilitate the selection of promising vaccine candidates for further evaluation. This approach, which makes use of whole genome sequence information, has the potential to greatly accelerate and facilitate the formulation of novel vaccines and is applicable to any pathogen that induces Abs in humans and/or experimental animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The haptoglobin-hemoglobin complex is also a viable source of iron for S. aureus and this complex is bound by IsdH (25, 27, 78) (Fig 1. B).”
From Molecular Mechanisms of Staphylococcus aureus Iron Acquisition (2011) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000) · Science · doi:10.1126/science.287.5459.1816 · Cited by 1,399
Navarre, W. W., & Schneewind, O. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.1.174-229.1999 · Cited by 1,391
Wizemann, T. M., Heinrichs, J. H., Adamou, J. E., Erwin, A. L., Kunsch, C., Choi, G. H., Barash, S. C., Rosen, C. A., Masure, H. R., Tuomanen, E., et al. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1593-1598.2001 · Cited by 351
Jungblut, P. R., Schaible, U. E., Mollenkopf, H. ‐., Zimny‐Arndt, U., Raupach, B., Mattow, J., Halada, P., Lamer, S., Hagens, K., & Kaufmann, S. H. E. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01549.x · Cited by 327
Folgori, A., Tafi, R., Meola, A., Felici, F., Galfré, G., Cortese, R., Monaci, P., & Nicosia, A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06501.x · Cited by 250
Kemp, D. J., Coppel, R. L., Cowman, A. F., Saint, R. B., Brown, G. V., & Anders, R. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3787 · Cited by 209
Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes
Mamula, M. J., & Mamula, M. J. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01223.x · Cited by 116
Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)
Snoeck, R., Noël, J., Muller, C., Clercq, E. D., & Bossens, M. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200002)60:2<144::aid-jmv7>3.0.co;2-g · Cited by 112
Chakravarti, D. N., Fiske, M. J., Fletcher, L. D., & Zagursky, R. J. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00256-5 · Cited by 108
Rennermalm, A., Li, Y., Bohaufs, L., Jarstrand, C., Brauner, A., Brennan, F. R., & Flock, J. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00080-9 · Cited by 101
Research works printed but not linked: 2
- Pereboeva L A, Pereboev A V, Wang L F, Morris G E. J Med Virol. 2000;60:144–151. [PubMed] [Google Scholar]
- Lorenz U, Ohlsen K, Karch H, Thiede A, Hacker J. FEMS Immunol Med Microbiol. 2000;29:145–153. doi: 10.1111/j.1574-695X.2000.tb01517.x. [DOI] [PubMed] [Google Scholar] · doi:10.1111/j.1574-695x.2000.tb01517.x · Paper page
Cited by
Antimicrobial resistance: the example of Staphylococcus aureus
Lowy, F. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18535 · Cited by 1,445
Immune evasion by staphylococci
Foster, T. J. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1289 · Cited by 1,222
“aureus antigens are present in all humans, and there is evidence that titres rise following infectio”
BackgroundGill, S. R., Fouts, D. E., Archer, G. L., Mongodin, E. F., DeBoy, R. T., Ravel, J., Paulsen, I. T., Kolonay, J. F., Brinkac, L., Beanan, M., et al. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.7.2426-2438.2005 · Cited by 1,026
“Variations in cell envelope or surface proteins, such as the LPXTG/NPQTN proteins and fibronectin binding proteins (encoded by fnbA and -B) likely reflect their immunogenicity and the high level of protective antibodies against these proteins which are present in human sera (18).”
BackgroundSelf-citationMolecular Mechanisms of Staphylococcus aureus Iron Acquisition
Hammer, N. D., & Skaar, E. P. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102851 · Cited by 379
“Structural analysis of the IsdH NEAT domains revealed that NEAT domain 1 binds both hemoglobin and haptoglobin.”
BackgroundInfluentialAntimicrobial resistance: the example of Staphylococcus aureus
Lowy, F. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318535 · Cited by 369
Giefing, C., Meinke, A. L., Hanner, M., Henics, T., Minh, D. B., Gelbmann, D., Lundberg, U., Senn, B. M., Schunn, M., Habel, A., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071168 · Cited by 271
Self-citationKuklin, N. A., Clark, D. J., Secore, S., Cook, J., Cope, L. D., McNeely, T., Noble, L., Brown, M. J., Zorman, J. K., Wang, X. M., et al. (2006) · Infection and Immunity · doi:10.1128/iai.74.4.2215-2223.2006 · Cited by 264
“aureus bacterial surface display libraries (8).”
BackgroundSelf-citationStaphylococcus colonization of the skin and antimicrobial peptides
Otto, M. (2010) · Expert Review of Dermatology · doi:10.1586/edm.10.6 · Cited by 262
“We know that humans have circulating antibodies against many staphylococcal proteins [87], but there is no general protective immunity from staphylococcal infection.”
BackgroundIron-regulated surface determinants (Isd) of Staphylococcus aureus: stealing iron from heme
P. Skaar, E., & Schneewind, O. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2003.12.008 · Cited by 209
“Investigations into IsdH, also known as HarA, have revealed that this protein is expressed during human infections and is immunogenic [26].”
BackgroundBrady, R. A., Leid, J. G., Camper, A. K., Costerton, J. W., & Shirtliff, M. E. (2006) · Infection and Immunity · doi:10.1128/iai.00392-06 · Cited by 222
“aureus proteins in acute infections that represent planktonic growth conditions (such as sepsis) have also been performed (26, 53, 63, 101, 103).”
BackgroundMethodInfluentialRoche, F. M., Massey, R., Peacock, S. J., Day, N. P. J., Visai, L., Speziale, P., Lam, A., Pallen, M., & Foster, T. J. (2003) · Microbiology · doi:10.1099/mic.0.25996-0 · Cited by 187
“SasI was also shown to be expressed during infection because sera from convalescent patients reacted with SasI peptides displayed on the surface of E. coli (Etz et al., 2002), while SdrD was identified by serological proteome analysis (Vytvytska et al., 2002).”
BackgroundClarke, S. R., Brummell, K. J., Horsburgh, M. J., McDowell, P. W., Mohamad, S. A. S., Stapleton, M. R., Acevedo, J., Read, R. C., Day, N. P. J., Peacock, S. J., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/501471 · Cited by 208
“However, this system required that all genes be cloned in-frame with the fusion protein and that the targets be amenable to expression in Escherichia coli [12].”
BackgroundGrifantini, R., Bartolini, E., Muzzi, A., Draghi, M., Frigimelica, E., Berger, J., Ratti, G., Petracca, R., Galli, G., Agnusdei, M., et al. (2002) · Nature Biotechnology · doi:10.1038/nbt728 · Cited by 205
“, we propose this microarray-based approach not as an alternative but rather as a complementary strategy to be used in parallel with other genomics and proteomics technologie”
MethodFrom empiricism to rational design: a personal perspective of the evolution of vaccine development
De Gregorio, E., & Rappuoli, R. (2014) · Nature Reviews Immunology · doi:10.1038/nri3694 · Cited by 204
“Although the path to licensure was slow for the meningococcus serogroup B vaccine, genome-based antigen discovery has been applied in one form or another to many other bacterial vaccines, including those against antibiotic-resistant bacteria, such as Staphylococcus aureus 64 .”
BackgroundFighting bacterial infections—Future treatment options
Fernebro, J. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.001 · Cited by 199
Bridging the knowledge gaps in vaccine design
Rappuoli, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1207-1361 · Cited by 185
Dryla, A., Prustomersky, S., Gelbmann, D., Hanner, M., Bettinger, E., Kocsis, B., Kustos, T., Henics, T., Meinke, A., & Nagy, E. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.3.387-398.2005 · Cited by 183
“In our previous work we used serum samples with high antistaphylococcal titers to identify novel antigens by a genome-wide method (14).”
BackgroundMethodInfluentialSelf-citationCurrent concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus
Watkins, R. R., David, M. Z., & Salata, R. A. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.043513-0 · Cited by 178
“In June 2011, Merck and Intercell announced the termination of phase II/III development of V170, a subunit vaccine containing the S. aureus antigen IsdB, which is a cell surface localized iron-regulated protein (Etz et al., 2002).”
BackgroundRinaudo, C. D., Telford, J. L., Rappuoli, R., & Seib, K. L. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38330 · Cited by 160
“A novel genome-based approach that combines serological antigen identification and the use of a comprehensive genomic peptide library, potentially expressing all genome-encoded amino acid sequences, has been recently developed and termed antigenomics (83).”
The contribution of immunology to the rational design of novel antibacterial vaccines
Kaufmann, S. H. E. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1688 · Cited by 186
Dryla, A., Gelbmann, D., Von Gabain, A., & Nagy, E. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03542.x · Cited by 153
“aureus as a function of epitope specific anti-HarA antibodies in an in vitro opsonophagocytosis assay (Etz et al., 2002).”
BackgroundInfluentialSelf-citationTwo years into reverse vaccinology
Adu‐Bobie, J. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00566-2 · Cited by 150
Post‐genomic vaccine development
Serruto, D., & Rappuoli, R. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.084 · Cited by 160
Palazzolo-Ballance, A. M., Reniere, M. L., Braughton, K. R., Sturdevant, D. E., Otto, M., Kreiswirth, B. N., Skaar, E. P., & DeLeo, F. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.500 · Cited by 142
“resistance to H2O2 and/or that absence of IsdA and IsdB, major protein components of the cell envelope (56, 57), alter properties”
BackgroundClarke, S. R., Harris, L. G., Richards, R. G., & Foster, S. J. (2002) · Infection and Immunity · doi:10.1128/iai.70.12.6680-6687.2002 · Cited by 133
“Furthermore, recent studies have identified it in a screen for genes expressed in vivo during human infection (10), and thus it is possible that this protein could have potential as a target in prophylaxis or therapy.”
BackgroundMora, M., Veggi, D., Santini, L., Pizza, M., & Rappuoli, R. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02689-8 · Cited by 129
Vaccination and passive immunisation against Staphylococcus aureus
Schaffer, A. C., & Lee, J. C. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.06.009 · Cited by 130
Development of a vaccine against Staphylococcus aureus
Spellberg, B. J., & Daum, R. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0293-5 · Cited by 134
Moisan, H., Brouillette, E., Jacob, C. L., Langlois-Bégin, P., Michaud, S., & Malouin, F. (2006) · Journal of Bacteriology · doi:10.1128/jb.188.1.64-76.2006 · Cited by 116
Towards the immune proteome of Staphylococcus aureus – The anti-S. aureus antibody response
Holtfreter, S., Kolata, J., & Bröker, B. M. (2009) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2009.10.002 · Cited by 133
“aureus proteins in a comprehensive manner, genomic expression libraries have been successfully applied: ribosome and phage display as well as bacterial expression (Clarke et al., 2006; Etz et al., 2002; Weichhart et al., 2003).”
BackgroundInfluentialNaz, K., Naz, A., Ashraf, S. T., Rizwan, M., Ahmad, J., Baumbach, J., & Ali, A. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2713-9 · Cited by 116
Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration
Harro, J. M., Peters, B. M., O'May, G. A., Archer, N., Kerns, P., Prabhakara, R., & Shirtliff, M. E. (2010) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2010.00708.x · Cited by 109
“The screens identify a large repertoire of antigenic peptides including those encoded by alternate reading frames (Etz et al., 2002).”
BackgroundAnderson, A. S., Miller, A. A., Donald, R. G. K., Scully, I. L., Nanra, J. S., Cooper, D., & Jansen, K. U. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.21872 · Cited by 116
Machine learning approaches for prediction of linear B‐cell epitopes on proteins
Söllner, J., & Mayer, B. (2006) · Journal of Molecular Recognition · doi:10.1002/jmr.771 · Cited by 111
“Here we describe the construction of machine learning based classifiers to enhance the prediction quality for identifying linear B-cell epitopes on proteins.”
MethodSelf-citationSolis, N., Larsen, M. R., & Cordwell, S. J. (2010) · PROTEOMICS · doi:10.1002/pmic.200900564 · Cited by 117
Surfome Analysis as a Fast Track to Vaccine Discovery
Doro, F., Liberatori, S., Rodríguez‐Ortega, M. J., Rinaudo, C. D., Rosini, R., Mora, M., Scarselli, M., Altındiş, E., D’Aurizio, R., Stella, M., et al. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800486-mcp200 · Cited by 111
“cinology” (2, 49, 50) or “immunomics” (51, 52) for vaccine”
Staphylococcal Vaccines and Immunotherapies
Schaffer, A. C., & Lee, J. C. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2008.10.005 · Cited by 108
The impact of genomics on vaccine design
Scarselli, M., Giuliani, M. M., Adu‐Bobie, J., Pizza, M., & Rappuoli, R. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.12.008 · Cited by 96
Marchetti, M., De Bei, O., Bettati, S., Campanini, B., Kovachka, S., Gianquinto, E., Spyrakis, F., & Ronda, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062145 · Cited by 97
Hu, D., Omoe, K., Sasaki, S., Sashinami, H., Sakuraba, H., Yokomizo, Y., Shinagawa, K., & Nakane, A. (2003) · The Journal of Infectious Diseases · doi:10.1086/377308 · Cited by 91
“This scenario has sparked renewed interest in the development of immunotherapeutics and vaccines [5-7].”
BackgroundGoncheva, M. I., Flannagan, R. S., Sterling, B. E., Laakso, H. A., Friedrich, N. C., Kaiser, J. C., Watson, D. W., Wilson, C. H., Sheldon, J. R., McGavin, M. J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08724-x · Cited by 89
Gil, C., Solano, C., Burgui, S., Latasa, C., García, B., Toledo‐Arana, A., Lasa, Í., & Valle, J. (2013) · Infection and Immunity · doi:10.1128/iai.01419-13 · Cited by 104
Groot, A. S. D., & Rappuoli, R. (2004) · Expert Review of Vaccines · doi:10.1586/14760584.3.1.59 · Cited by 97
Current methodologies for proteomics of bacterial surface‐exposed and cell envelope proteins
Solis, N., & Cordwell, S. J. (2011) · PROTEOMICS · doi:10.1002/pmic.201000808 · Cited by 87
“Bioinformatic and genomic methods have been applied to a variety of organisms [15, 25, 35, 42, 43] with relative success.”
MethodNovel targeted immunotherapy approaches for staphylococcal infection
Otto, M. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.495115 · Cited by 93
“aureus peptide libraries were screened with patient sera and the surface protein IsdB was selected as an antigen [26,27].”
MethodGlowalla, E., Tosetti, B., Krönke, M., & Krut, O. (2009) · Infection and Immunity · doi:10.1128/iai.00617-08 · Cited by 94
“Indeed, numerous staphylococcal surface proteins predicted to be promising antigenic targets have been identified so far using recently adopted technologies, like proteomics (19, 36, 57) or protein selection methods based on expression libraries (10, 13, 58, 59).”
BackgroundA comprehensive comparison of DNA and RNA vaccines
Wang, C., & Yuan, F. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115340 · Cited by 105
In vivo induced antigen technology (IVIAT)
Rollins, S. M., Peppercorn, A., Hang, L., Hillman, J. D., Calderwood, S. B., Handfield, M., & Ryan, E. T. (2004) · Cellular Microbiology · doi:10.1111/j.1462-5822.2004.00477.x · Cited by 83
Varrone, J. J., de Mesy Bentley, K. L., Bello-Irizarry, S. N., Nishitani, K., Mack, S., Hunter, J. G., Kates, S. L., Daiss, J. L., & Schwarz, E. M. (2014) · Journal of Orthopaedic Research · doi:10.1002/jor.22672 · Cited by 79
“For these reasons we have focused our efforts on the glucosaminidase (Gmd) subunit of autolysin (Atl), which several groups have identified as an immunodominant antigen.(29,30) Functionally, Atl has been shown to be essential for cell wall biosynthesis and degradation during binary fission.”
BackgroundReverse Vaccinology: An Approach for Identifying Leptospiral Vaccine Candidates
Dellagostin, O. A., Grassmann, A. A., Rizzi, C., Schuch, R. A., Jorge, S., de Oliveira, T. M., McBride, A. J. A., & Hartwig, D. D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010158 · Cited by 80
“Similarly, an immune correlate assay based on the opsonophagocytosis of Staphylococcus aureus was essential for the identification of vaccine antigens [114].”
BackgroundLei, B., Liu, M., Chesney, G. L., & Musser, J. M. (2004) · The Journal of Infectious Diseases · doi:10.1086/380491 · Cited by 80
“For example, serologic proteome analysis has been used to identify novel candidate vaccine antigens in GAS [45], Staphylococcus aureus [57], and Helicobacter pylori [58].”
BackgroundStaphylococcus aureus vaccines: Deviating from the carol
Missiakas, D. M., & Schneewind, O. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20160569 · Cited by 86
“2016 Vol. 213 No. 9 1645–1653 www.jem.org/cgi/doi/10.1084/jem.20160569 1645”
MethodInfluentialDesigning the Next Generation of Vaccines for Global Public Health
Bagnoli, F., Baudner, B. C., Mishra, R. P. N., Bartolini, E., Fiaschi, L., Mariotti, P., Nardi‐Dei, V., Boucher, P., & Rappuoli, R. (2011) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2010.0127 · Cited by 90
“In another recent publication, Bombaci et al. (2009) generated a Group A Streptococcus (GAS) antigen array, by spotting 102 different proteins, to investigate the relationship between the antibody response against GAS antigens and the TIC neurologic disorder.”
InfluentialTroidle, L. K., Gorban‐Brennan, N., Kliger, A. S., & Finkelstein, F. O. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16095.x · Cited by 89
“(102) developed amethodology that identified 60 antigenic proteins with little sequence variation that are on the surface of S.”
BackgroundKolata, J., Bode, L. G. M., Holtfreter, S., Steil, L., Kusch, H., Holtfreter, B., Albrecht, D., Hecker, M., Engelmann, S., van Belkum, A., et al. (2011) · PROTEOMICS · doi:10.1002/pmic.201000760 · Cited by 84
“The autolysins (Atl and Aaa) and the glycerol phosphate lipoteichoic acid synthase (LtaS) are involved in the bacterial cell wall metabolism; Atl has previously been recognized as an immune dominant antigen by several groups [24, 42, 44, 45].”
BackgroundDryla, A., Hoffmann, B., Gelbmann, D., Giefing, C., Hanner, M., Meinke, A., Anderson, A. S., Koppensteiner, W., Konrat, R., von Gabain, A., et al. (2007) · Journal of Bacteriology · doi:10.1128/jb.01366-06 · Cited by 73
“They all induce high levels of antibodies during human infections, suggesting a high level of in vivo expression (16).”
BackgroundSelf-citationFritzer, A., Senn, B. M., Minh, D. B., Hanner, M., Gelbmann, D., Noiges, B., Henics, T., Schulze, K., Guzmán, C. A., GOODACRE, J. A., et al. (2010) · Infection and Immunity · doi:10.1128/iai.00295-10 · Cited by 76
Self-citationHuman Immune Proteome in Experimental Colonization with Staphylococcus aureus
Holtfreter, S., Nguyen, T. T. H., Wertheim, H. F. L., Steil, L., Kusch, H., Truong, Q. P., Engelmann, S., Hecker, M., Völker, U., van Belkum, A., et al. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00263-09 · Cited by 72
“aureus antibodies against staphylococcal toxins, immune evasion molecules, and adhesins have been detected in healthy individuals as well as in patients (6, 7, 11, 31).”
BackgroundThe Genome Revolution in Vaccine Research
Capecchi, B., Serruto, D., Adu‐Bobie, J., Rappuoli, R., & Pizza, M. (2004) · Current Issues in Molecular Biology · doi:10.21775/cimb.006.017 · Cited by 86
“Pathogens that have been studied include S. pneumoniae (Wizemann et al., 2001), S. aureus (Etz et al., 2002; Vytvytska et al., 2002), C. pneumoniae (Montigiani et al., 2002), Porhyromonas gingivalis (Ross et al., 2001), Edwardsiella tarda (Srinivasa Rao et al., 2003), and M. tuberculosis (Betts,…”
BackgroundWeichhart, T., Horky, M., Söllner, J., Gangl, S., Henics, T., Nagy, E., Meinke, A. L., von Gabain, A., Fraser, C. M., Gill, S. R., et al. (2003) · Infection and Immunity · doi:10.1128/iai.71.8.4633-4641.2003 · Cited by 73
“The number of clones matching a particular ORF varies considerably, most probably reflecting corresponding antibody abundance and/or affinity (4).”
BackgroundMethodInfluentialSelf-citationAntigenome technology: a novel approach for the selection of bacterial vaccine candidate antigens
Meinke, A. L., Henics, T., Hanner, M., Minh, D. B., & NAGY, E. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.005 · Cited by 66
Self-citationReverse Vaccinology and Vaccines for Serogroup B Neisseria meningitidis
Kelly, D. F., & Rappuoli, R. (2007) · Springer eBooks · doi:10.1007/0-387-25342-4_15 · Cited by 62
Adaptive Immunity Against Staphylococcus aureus
Karaüzüm, H., & Datta, S. K. (2016) · Current topics in microbiology and immunology · doi:10.1007/82_2016_1 · Cited by 76
“coli expression library (Etz et al. 2002).”
BackgroundImmunotherapeutic strategies to combat staphylococcal infections
Ohlsen, K., & Lorenz, U. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.04.015 · Cited by 74
Teng, Y.-T. A. (2006) · Journal of Dental Research · doi:10.1177/154405910608500302 · Cited by 66
“(ii) In vivo-induced Antigen Technology (IVIAT) This is a modified immunologic screening technique primarily based on the use of sera from infected patients to probe a protein expression library to identify antigens expressed specifically in vivo during human infections (see Etz et al., 2002).”
BackgroundA Universal Vaccine against Leptospirosis: Are We Going in the Right Direction?
Grassmann, A. A., Grassmann, J. D. S., & McBride, A. J. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00256 · Cited by 65
“, the bactericidal assay for Neisseria meningitidis (91) and the opsonophagocytosis assay for Staphylococcus aureus (92).”
BackgroundCurrent status and future prospects for a vaccine against American trypanosomiasis
Garg, N. J., & Bhatia, V. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.6.867 · Cited by 59
Serruto, D., Adu‐Bobie, J., Capecchi, B., Rappuoli, R., Pizza, M., & Masignani, V. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.03.024 · Cited by 58
Lorenz, U., Lorenz, B., Schmitter, T., Streker, K., Erck, C., Wehland, J., Nickel, J., Zimmermann, B., & Ohlsen, K. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-10 · Cited by 59
“aureus to determine which bacterial antigens are associated with protective antistaphylococcal antibodies (4, 7, 9, 24, 27, 39).”
BackgroundTargeted Immunotherapy for Staphylococcal Infections: Focus on Anti-MSCRAMM Antibodies
Otto, M. J. (2008) · BioDrugs · doi:10.2165/00063030-200822010-00003 · Cited by 64
Bacterial surface proteins and vaccines
Grandi, G. (2010) · F1000 Biology Reports · doi:10.3410/b2-36 · Cited by 64
“The expression libraries are then screened with sera from patients infected by the pathogen of interest and the identified immunogenic proteins are tested for their capacity to elicit protective immunity in animal models [7].”
BackgroundTargeting Virulence for Antibacterial Chemotherapy
Marra, A. (2006) · Drugs in R&D · doi:10.2165/00126839-200607010-00001 · Cited by 46
Strategies for and advances in the development ofStaphylococcus aureusprophylactic vaccines
Broughan, J. H., Anderson, R. J., & Anderson, A. S. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.54 · Cited by 56
The global need for effective antibiotics—A summary of plenary presentations
Alván, G., Edlund, C., & Heddini, A. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.01.007 · Cited by 62
Developing Antibacterial Vaccines in Genomics and Proteomics Era
Kaushik, D., & Sehgal, D. (2008) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2008.02107.x · Cited by 57
Novel Developments in the Prevention, Diagnosis, and Treatment of Periprosthetic Joint Infections
Parvizi, J., Alijanipour, P., Barberi, E., Hickok, N. J., Phillips, K. S., Shapiro, I. M., Schwarz, E. M., Stevens, M. H., Wang, Y., & Shirtliff, M. E. (2015) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-14-00455 · Cited by 52
Staphylococcus aureus: the search for novel targets
García-Lara, J., Masalha, M., & Foster, S. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03432-x · Cited by 69
Identification and characterization of antigens as vaccine candidates againstKlebsiella pneumoniae
Lundberg, U., Senn, B. M., Schüler, W., Meinke, A. L., & Hanner, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23225 · Cited by 60
“In order to identify immunoreactive Klebsiella proteins, both LamB and FhuA bacterial surface display libraries were incubated with human IgG pools as described previously.(18) Using streptavidin-coated microbeads, clones carrying inserts recognized by antibodies were separated by magnetic-activated cell sorting (MACS…”
InfluentialSelf-citationMohamed, N., Timofeyeva, Y., Jamrozy, D., Rojas, E., Hao, L., Silmon de Monerri, N. C., Hawkins, J., Singh, G., Cai, B., Liberator, P., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0208356 · Cited by 48
Taverna, F., Negri, A. L., Piccinini, R., Zecconi, A., Nonnis, S., Ronchi, S., & Tedeschi, G. (2007) · Veterinary Microbiology · doi:10.1016/j.vetmic.2006.09.007 · Cited by 53
“aureus and the availability of reproducible proteomic procedures to evaluate the pattern of antibody expressed by infected versus healthy subjects will provide new information for developing vaccines and diagnostic tools (Etz et al., 2002; Sellman et al., 2005; Vytvytska et al., 2002; Weichhart et al., 2003).”
BackgroundBowden, C. F. M., Chan, A. C. K., Li, E. J. W., Arrieta, A. L., Eltis, L. D., & Murphy, M. E. P. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.806562 · Cited by 48
Murray, G. L., Lo, M., Bulach, D., Srikram, A., Seemann, T., Quinsey, N. S., Sermswan, R. W., Allen, A., & Adler, B. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.11.028 · Cited by 52
Staphylococcus aureus seroproteomes discriminate ruminant isolates causing mild or severe mastitis
Maréchal, C. L., Jardin, J., Jan, G., Even, S., Pulido, C., Guibert, J.-M., Hernández, D., François, P., Schrenzel, J., Demon, D., et al. (2011) · Veterinary Research · doi:10.1186/1297-9716-42-35 · Cited by 55
“atl autolysin 23, 31 011_1991 046_0320 SAOV_0999c 9,59 136983 2567,68 42,14 42 1,87 S S [52,76,93]”
InfluentialCan virulence factors be viable antibacterial targets?
Marra, A. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.1.61 · Cited by 53
Vaccine potential of novel surface exposed and secreted proteins of Streptococcus equi
Timoney, J. F., Qin, A., Muthupalani, S., & Artiushin, S. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.040 · Cited by 46
Identification of a surface protective antigen, HP0197 of Streptococcus suis serotype 2
Zhang, A., Chen, B., Li, R., Mu, X., Han, L., Zhou, H., Chen, H., & Meilin, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.06.074 · Cited by 51
Evaluation of the Leptospira interrogans Outer Membrane Protein OmpL37 as a Vaccine Candidate
Oliveira, T. L., Grassmann, A. A., Schuch, R. A., Neto, A. C. P. S., Mendonça, M., Hartwig, D. D., McBride, A. J. A., & Dellagostin, O. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142821 · Cited by 43
Tordello, E. D., Rappuoli, R., & Delany, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802302-0.00002-9 · Cited by 54
Soltan, M. A., Magdy, D., Solyman, S. M., & Hanora, A. (2020) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2019.0183 · Cited by 43
“The choice of blood samples from human in this study as the source of antibody to be tested against our vaccine candidate in Western blot was consistent with what was reported in many studies as the study of Etz et al. (2002).”
Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
Kim, C.-M., & Shin, S.-H. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2009.24.2.289 · Cited by 42
“Similarly, iron-chelation therapies capable of preventing bacterial iron-uptake have also received attention as attractive novel preventive or therapeutic modalities (3-7).”
BackgroundVaccines for parasitic and bacterial diseases
Reed, S. G., & Campos‐Neto, A. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00069-4 · Cited by 48
Application of Microbial Genomic Science to Advanced Therapeutics
Fraser, C. M., & Rappuoli, R. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144853 · Cited by 40
“The application of reverse vaccinology to the study of this difficult pathogen has led to the identification of many novel vaccine candidates (48).”
BackgroundSelf-citationDiep, B. A., Phung, Q., Date, S., Arnott, D., Bakalarski, C., Xu, M., Nakamura, G., Swem, D. L., Alexander, M. K., Le, H. N., et al. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit662 · Cited by 38
“aureus during host infection [18, 19], or conducting proteomic analysis under in vitro conditions that were thought to mimic the in vivo”
BackgroundShao, Z., Pan, X., Li, X., Liu, W., Han, M., Wang, C., Wang, J., Zheng, F., Cao, M., & Tang, J. (2011) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2010.02162.x · Cited by 36
Exploring Staphylococcus aureus pathways to disease for vaccine development
DeDent, A. C., Kim, H. K., Missiakas, D. M., & Schneewind, O. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0299-z · Cited by 41
“binant surface displaced polypeptides using sera from patients suffering from acute staphylococcal infections [75].”
BackgroundRole and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus
Ferraro, A., Buonocore, S. M., Auquier, P., Nicolas, I., Wallemacq, H., Boutriau, D., & der Most, R. G. V. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1613126 · Cited by 39
Progress in Vaccine Development
Moyle, P. M. (2015) · Current Protocols in Microbiology · doi:10.1002/9780471729259.mc1801s36 · Cited by 35
Bioinformatics: how it is being used to identify bacterial vaccine candidates
Zagursky, R. J., Olmsted, S. B., Russell, D. P., & Wooters, J. L. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.3.417 · Cited by 37
“Etz and colleagues describe an interesting extension of research that has been afforded by genomic sequencing [171] .”
Molecular Basis of Pathogenicity
Smeltzer, M. S., Lee, C. Y., Harik, N., & Hart, M. E. (2009) · Wiley eBooks · doi:10.1002/9781444308464.ch4 · Cited by 44
Immune proteomics of Staphylococcus aureus
Bröker, B. M., & van Belkum, A. (2011) · PROTEOMICS · doi:10.1002/pmic.201100010 · Cited by 42
“Other groups have reported immune dominance of extracellular and surface-exposed antigens that are accessible to B cells [40, 41].”
Background
Metadata
- Authors
- Etz, H., Minh, D. B., Henics, T., Dryla, A., Winkler, B., Triska, C., Boyd, A. P., Söllner, J., Schmidt, W., von Ahsen, U., Buschle, M., Gill, S. R., Kolonay, J., Khalak, H., Fraser, C. M., von Gabain, A., Nagy, E., & Meinke, A.
- Affiliations
- Intercell (Austria) (AT)
- InterCell Biomedizinische Forschungs- und Entwicklungs-AG, Campus Vienna Biocenter 6, 1030 Vienna, Austria; and Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850
- Corresponding author
- Meinke, Andreas
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-05-07
- Volume
- 99
- Issue
- 10
- Pages
- 6573-6578
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC124444
- OpenAlex
- W1999985155
- Cited by
- 218
- References
- 21
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 9 · 2012: 13
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
- Keywords
- Staphylococcus aureus, vaccine candidate antigens, subunit vaccine design, antigen identification, opsonic activity, lambs, FhuA, surface-exposed proteins, secreted proteins, whole genome sequencing, serological reactivity
- MeSH terms
- Amino Acid Sequence, Animals, Antigens, Bacterial, Bacterial Outer Membrane Proteins, Base Sequence, DNA, Bacterial, Humans, Macrophages, Mice, Inbred BALB C, Molecular Sequence Data, Phagocytosis, Receptors, Virus, Recombinant Fusion Proteins, Staphylococcal Infections, Staphylococcal Vaccines, Staphylococcus aureus, Vaccines, Synthetic, Genomic Library, Gene Expression, Genome, Bacterial, Porins, Epitopes, B-Lymphocyte, Escherichia coli Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.